Drugs / PF-07934040
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06447662 | Jun 2024 → Oct 2026 expected | colorectal neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Pfizer | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07934040 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06447662 ↗ |
| Action | Inhibit | “panKRAS inhibitor” NCT06447662 ↗ |
| Route | Oral | “All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day” NCT06447662 ↗ |
| Target | KRAS | “panKRAS inhibitor” NCT06447662 ↗ |